Patients using older GLP-1 medications like Byetta are increasingly transitioning to newer therapies such as Wegovy and Zepbound. Here’s how the switching process works, why dose escalation matters, and what clinicians consider when choosing between semaglutide and tirzepatide.
Semaglutide, tirzepatide, and retatrutide represent three generations of obesity medications. Here’s how GLP-1, dual-agonist, and triple-agonist therapies compare for weight loss, metabolism, and future obesity treatment.
Retatrutide is an investigational triple-agonist weight loss injection targeting GLP-1, GIP, and glucagon receptors simultaneously. Early trials suggest it may outperform current obesity medications, including Wegovy and Mounjaro.
Retatrutide may become the next major breakthrough in obesity medicine. Here’s how the investigational triple-agonist compares with Wegovy, Mounjaro, and other GLP-1 medications for weight loss and metabolic health.
As tirzepatide and semaglutide drive larger weight-loss results, questions about muscle preservation and body composition are becoming increasingly important in obesity medicine.
A major clinical trial found that tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Here’s what researchers believe explains the difference between these two leading obesity medications.
New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.
Semaglutide medications like Ozempic and Wegovy suppress appetite and accelerate weight loss, but experts warn that inadequate protein intake may increase the risk of muscle loss. Here’s why protein has become a major focus for GLP-1 users and how clinicians recommend protecting lean mass during treatment.
Rapid weight loss from GLP-1 medications can accelerate facial aging through volume depletion and collagen loss. This in-depth guide compares Sculptra vs. Radiesse for restoring facial structure, tightening skin, and treating “Ozempic Face.”
GLP-1 drugs have transformed obesity treatment, with tirzepatide now leading in effectiveness. Here’s what the latest 2026 evidence reveals about safety, results, and future therapies.